Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

Open access
Moujalled, Donia M., Pomilio, Giovanna, Ghiurau, Corina, Ivey, Adam, Salmon, Jessica, Rijal, Sewa, Macraild, Sarah, Zhang, Lan, Teh, Tse-Chieh, Tiong, Ing-Soo, Lan, Ping, Chanrion, Maia, Claperon, Audrey, Rocchetti, Francesca, Zichi, Adrien, Kraus-Berthier, Laurence, Wang, Youzhen, Halilovic, Ensar, Morris, Erick, Colland, Frédéric, Segal, David, Huang, David, Roberts, Andrew W., Maragno, Ana Leticia, Lessene, Guillaume, Geneste, Olivier, Wei, Andrew H. · 2019 · Leukemia

Abstract

Improving outcomes in acute myeloid leukemia (AML) remains a major clinical challenge. Overexpression of pro-survival BCL-2 family members rendering transformed cells resistant to cytotoxic drugs is a common theme in cancer. Targeting BCL-2 with the BH3-mimetic venetoclax is active in AML when combined with low-dose chemotherapy or hypomethylating agents. We now report the pre-clinical anti-leukemic efficacy of a novel BCL-2 inhibitor S55746, which demonstrates synergistic pro-apoptotic activity in combination with the MCL1 inhibitor S63845. Activity of the combination was caspase and BAX/BAK dependent, superior to combination with standard cytotoxic AML drugs and active against a broad spectrum of poor risk genotypes, including primary samples from patients with chemoresistant AML. Co-targeting BCL-2 and MCL1 was more effective against leukemic, compared to normal hematopoietic progenitors, suggesting a therapeutic window of activity. Finally, S55746 combined with S63845 prolonged survival in xenograft models of AML and suppressed patient-derived leukemia but not normal hematopoietic cells in bone marrow of engrafted mice. In conclusion, a dual BH3-mimetic approach is feasible, highly synergistic, and active in diverse models of human AML. This approach has strong clinical potential to rapidly suppress leukemia, with reduced toxicity to normal hematopoietic precursors compared to chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-018-0261-3

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 174

Metadata

Authors
Moujalled, D. M., Pomilio, G., Ghiurau, C., Ivey, A., Salmon, J., Rijal, S., Macraild, S., Zhang, L., Teh, T.-C., Tiong, I.-S., Lan, P., Chanrion, M., Claperon, A., Rocchetti, F., Zichi, A., Kraus-Berthier, L., Wang, Y., Halilovic, E., Morris, E., Colland, F., Segal, D., Huang, D., Roberts, A. W., Maragno, A. L., Lessene, G., Geneste, O., & Wei, A. H.
Venue
Leukemia
Published
2018-09-10
Volume
33
Issue
4
Pages
905-917
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2889850618
Cited by
174
References
8
FWCI
15.20
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. https://app.cochat.ai/papers/10.1038/s41375-018-0261-3
The paper
Moujalled, D. M., Pomilio, G., Ghiurau, C., Ivey, A., Salmon, J., Rijal, S., Macraild, S., Zhang, L., Teh, T.-C., Tiong, I.-S., Lan, P., Chanrion, M., Claperon, A., Rocchetti, F., Zichi, A., Kraus-Berthier, L., Wang, Y., Halilovic, E., Morris, E., . . . Wei, A. H. (2019). Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia. https://doi.org/10.1038/s41375-018-0261-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.